What does this research mean for the field?

Long-term routine laboratory toxicity monitoring (lt-RLTM) during DMARD therapy in rheumatoid arthritis patients reveals that most very abnormal results are anticipated and often occur after dose increases, suggesting a need to reconsider monitoring strategies. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to evaluate the incidence of abnormal laboratory results during long-term DMARD therapy in rheumatoid arthritis patients.

February 28, 2026Kompass Autoimmun

Rheumatoide Arthritis: Langzeitkontrolle der DMARD-Therapie besser individualisiert als routinemäßig?

View Full Paper

Ask AI

Bookmark

Authors

CMCarina Mihai

Discussion

Member takes

Overview

Retrospective cohort study determines abnormal laboratory results in rheumatoid arthritis, suggesting a need for individualized monitoring.

Key Points

This study aims to evaluate the incidence of abnormal laboratory results during long-term DMARD therapy in rheumatoid arthritis patients.
Conducted a retrospective cohort study in the Netherlands from July 2008 to April 2020.
Included patients with rheumatoid arthritis undergoing long-term routine laboratory toxicity monitoring (lt-RLTM) after at least 6 months of DMARD use.
Calculated cumulative probabilities of abnormal laboratory results for key tests: alanine aminotransferase, eGFR, hemoglobin, leukocyte count, and platelet count.
Performed chart reviews to characterize the clinical context of newly occurring very abnormal results.
4774 patients underwent 59,555 lt-RLTM test sets over 18,383 patient-years.
Very abnormal laboratory results for tested areas ranged from 0.2% (leukocyte count) to 6.6% (eGFR) at 2 years and 0.3% to 11% at 5 years.
New very abnormal results mostly occurred after dose increases and were often pre-existing or unrelated to DMARD use.
The incidence of less serious abnormal results was significant, with 39% eGFR below 60 mL/min and 61% hemoglobin levels below threshold.

Cite This Study

Carina Mihai (2026) studied this question.

synapsesocial.com/papers/69a2878e0a974eb0d3c03520 https://doi.org/10.1159/000550567

View Full Paper

Ask AI

Bookmark

February 28, 2026Kompass Autoimmun

Rheumatoide Arthritis: Langzeitkontrolle der DMARD-Therapie besser individualisiert als routinemäßig?

View Full Paper

Ask AI

Bookmark

Authors

CMCarina Mihai

Discussion

Member takes

Overview

Retrospective cohort study determines abnormal laboratory results in rheumatoid arthritis, suggesting a need for individualized monitoring.

Key Points

This study aims to evaluate the incidence of abnormal laboratory results during long-term DMARD therapy in rheumatoid arthritis patients.
Conducted a retrospective cohort study in the Netherlands from July 2008 to April 2020.
Included patients with rheumatoid arthritis undergoing long-term routine laboratory toxicity monitoring (lt-RLTM) after at least 6 months of DMARD use.
Calculated cumulative probabilities of abnormal laboratory results for key tests: alanine aminotransferase, eGFR, hemoglobin, leukocyte count, and platelet count.
Performed chart reviews to characterize the clinical context of newly occurring very abnormal results.
4774 patients underwent 59,555 lt-RLTM test sets over 18,383 patient-years.
Very abnormal laboratory results for tested areas ranged from 0.2% (leukocyte count) to 6.6% (eGFR) at 2 years and 0.3% to 11% at 5 years.
New very abnormal results mostly occurred after dose increases and were often pre-existing or unrelated to DMARD use.
The incidence of less serious abnormal results was significant, with 39% eGFR below 60 mL/min and 61% hemoglobin levels below threshold.

Cite This Study

Carina Mihai (2026) studied this question.

synapsesocial.com/papers/69a2878e0a974eb0d3c03520 https://doi.org/10.1159/000550567

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark